drugset
drugset / Trial / NCT07134205

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

NCT07134205 ↗

Phase 3 Not yet recruiting 252 enrolled Shanghai JMT-Bio Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.

Timeline

Start
2025-10-01
Primary completion
2027-06-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BECOTATUG Monoclonal antibody 6 mg/kg Intravenous
Subject Irinotecan Small molecule 180 mg/m2 Intravenous
Comparator Regorafenib Small molecule 160 mg Oral

Indications

colorectal cancer